Australasian Equities

Equity Research
Archive
Australasian Equities

Sample Reports | Old Reports | Not Current

Core

medium

Profit Surges on Record Fund Inflows Generation Development Group (ASX: GDG) recently reported underlying profit jumped 63% to $20.1 million for the 1H26 as funds under management hit record levels, with investment bonds reaching $5.2 billion and managed accounts climbing to $34.5 billion. Revenue rose 35% to $88.4 million with operating margins expanding as growth outpaced costs. The company maintained 60% market share of investment bond inflows on record gross sales of $723 million. GDG closed +3.6% higher after the result as

Collins Foods

Core

medium

Taking over Deutschland Collins Foods (ASX: CKF) announced yesterday that it will pay €31.1 million for eight KFC restaurants in Bavaria, Germany, and has signed agreements to open 45-90 new stores across three German states by 2029. The Bavarian outlets generate €28.2 million annual revenue at higher margins than existing German stores. The company refocused their Dutch operations and will hand marketing back to brand owner Yum! in January 2027. Australian same-store sales rose 2.7% year-to-date while German sales climbed 4.5%.

CSL

Core

medium

Illinois Expansion Targets 2031 Completion CSL (ASX: CSL) announced yesterday a $1.5 billion expansion of its Illinois plasma manufacturing facility, adding 330,000 square feet and 300 permanent jobs to bring the entire US plasma value chain onshore by around 2031. The project will incorporate new yield-enhancing technology to extract more immunoglobulin from each litre of plasma, targeting 100% of US demand for key brands once operational. This follows over $3 billion already invested in US operations since 2018. Shares were roughly

Fortescue

Speculative

high

Copper Acquisition and Solar Project Advance Fortescue’s (ASX: FMG) C$139 million acquisition of Alta Copper secures 100% ownership of Peru’s Cañariaco copper project, and the company is also starting construction on a 440MW solar farm at Solomon Airport in the Pilbara. The solar plant will be Western Australia’s largest and provide one-third of the capacity needed to hit the company’s operational emissions target. Management will take a staged approach to Cañariaco through technical reviews and community engagement rather than immediately deploying capital.

BHP

Core

medium

The Dip Has Been Served. Pick Up the Fork. BHP’s journey from its record high in early March near $60 to the $51 level in little over a week looks dramatic in isolation. We view it as a textbook post-euphoria consolidation to breakout support, and we believe the risk-reward from current levels favours buyers. The BUY thesis is intact. The sell-off is the product of a few overlapping forces, none of which, individually or collectively, alters the fundamental investment case. We

Qantas

Core

high

Profit Up; Shares Nosedive on ME Fears Qantas Airways (ASX: QAN) was understandably underwater on Monday. The airline reported on 26th February that 1H26 profit before tax rose 5% to $1.46 billion as revenue climbed 6% to $12.9 billion, though market concerns over Middle East tensions and oil price expectations have been weighing recently. Domestic earnings jumped 14% to $1.05 billion as new Airbus aircraft lifted fuel efficiency and on-time performance. International margins compressed to 6.2% from 7.4% on higher costs and

After the Fall: What 20 Years of ASX Data Tells Us About Big Days

Riding the volatility – when the ASX200 has a big move on the day, just how big a deal is it historically? A fall of 2%, let alone the 2.85% drop we saw on Monday, dominates the news cycle, which leads to fear and a lot of emotional trading. Big days are always emotional days, and fear is a stronger emotion than greed when it comes to large market drawdowns, like we saw yesterday. On these days, the satisfaction investors generally

CSL

Core

medium

A ‘Shot’ in the Arm Eh? CSL (ASX: CSL) shares rose after Canada renewed a pandemic preparedness contract with CSL Seqirus for up to 15 million doses of cell-based influenza vaccine, adding to existing agreements with 17 European countries and Australia. The deal highlights the vaccine division’s strategic value as CSL attempts to rebuild confidence after shares hit eight-year lows in February following an 81% reported profit drop on impairments and CEO Paul McKenzie’s exit. Management maintained full-year guidance for 4%-7% profit

About these archived stock reports

These are archived Fat Prophets equity research stock reports and share analysis. They do not constitute current investment advice, financial product advice, or a recommendation to buy, sell or hold any financial product. They are provided for historical reference only, and reflect the market conditions, company information, forecasts and opinions available at its original publication date. The information may no longer be current or applicable. Past performance is not a reliable indicator of future performance.

This is general information only and does not take into account your objectives, financial situation or needs. Before acting on anything in this report, you should consider its appropriateness to your circumstances and seek advice from a licensed financial adviser.

DISCLAIMER Fat Prophets has made every effort to ensure the reliability of the views and recommendations expressed in the reports published on its websites. Fat Prophets research is based upon information known to us or which was obtained from sources which we believed to be reliable and accurate at time of publication. However, like the markets, we are not perfect. This report is prepared for general information only, and as such, the specific needs, investment objectives or financial situation of any particular user have not been taken into consideration. Individuals should therefore discuss, with their financial planner or advisor, the merits of each recommendation for their own specific circumstances and realise that not all investments will be appropriate for all subscribers. To the extent permitted by law, Fat Prophets and its employees, agents and authorised representatives exclude all liability for any loss or damage (including indirect, special, or consequential loss or damage) arising from the use of, or reliance on, any information within the report whether or not caused by any negligent act or omission. If the law prohibits the exclusion of such liability, Fat Prophets hereby limits its liability, to the extent permitted by law, to the resupply of the said information or the cost of the said resupply.

Funds Management – In addition to the listed fund FPC, Fat Prophets Pty Ltd manages the separately managed accounts, namely Concentrated Australian Shares, Australian Shares Income, Small Midcap, Global Opportunities, Mining & Resources, and Asian Shares. These SMAs are managed under their own mandates by the fund managers, and this is independent to the research reports.

Staff trading – Fat Prophets Pty Ltd, its directors, employees and associates of Fat Prophets may hold interests in many ASX-listed Australian companies which may or may not be mentioned or recommended in the Fat Prophets newsletter. These positions may change at any time, without notice. To manage the conflict between personal dealing and newsletter recommendations the directors, employees, and associates of Fat Prophets Pty Ltd cannot knowingly trade in a stock 48 hours either side of a buy or sell recommendation being made in the Fat Prophets newsletter. Staff trades are pre-approved by an appointed staff trading compliance officer to ensure compliance with the staff trading policy.

For positions that directors and/or associates of the Fat Prophets group of companies currently hold in, please click here.